296 related articles for article (PubMed ID: 28841415)
1. Cancer Evolution Constrained by the Immune Microenvironment.
McGranahan N; Swanton C
Cell; 2017 Aug; 170(5):825-827. PubMed ID: 28841415
[TBL] [Abstract][Full Text] [Related]
2. Immune Tumor Microenvironment in Ovarian Cancer Ascites.
Almeida-Nunes DL; Mendes-Frias A; Silvestre R; Dinis-Oliveira RJ; Ricardo S
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142615
[TBL] [Abstract][Full Text] [Related]
3. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the immune microenvironment in ovarian cancer patients.
Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
[TBL] [Abstract][Full Text] [Related]
5. Fine-grained simulations of the microenvironment of vascularized tumours.
Fredrich T; Rieger H; Chignola R; Milotti E
Sci Rep; 2019 Aug; 9(1):11698. PubMed ID: 31406276
[TBL] [Abstract][Full Text] [Related]
6. A Darwinian perspective on tumor immune evasion.
Puleo J; Polyak K
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188671. PubMed ID: 34933050
[TBL] [Abstract][Full Text] [Related]
7. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
Jäntti T; Luhtala S; Mäenpää J; Staff S
Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
[TBL] [Abstract][Full Text] [Related]
8. Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer.
Heindl A; Lan C; Rodrigues DN; Koelble K; Yuan Y
Oncotarget; 2016 Nov; 7(44):71123-71135. PubMed ID: 27661102
[TBL] [Abstract][Full Text] [Related]
9. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
10. Cancer evolution: Special focus on the immune aspect of cancer.
Hu X; Chen Z; Wang Z; Xiao Q
Semin Cancer Biol; 2022 Nov; 86(Pt 2):420-435. PubMed ID: 35589072
[TBL] [Abstract][Full Text] [Related]
11. The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer.
Launonen IM; Vähärautio A; Färkkilä A
Cold Spring Harb Perspect Med; 2023 Oct; 13(10):. PubMed ID: 37553211
[TBL] [Abstract][Full Text] [Related]
12. Discovering Anti-cancer Immune Enhancers in a Miniaturized Immune-Tumor Microenvironment.
Huber AD; Chen T
Cell Chem Biol; 2019 Mar; 26(3):314-316. PubMed ID: 30901558
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
Sue-A-Quan R; Patel PG; Shakfa N; Nyi MN; Afriyie-Asante A; Kang EY; Köbel M; Koti M
Gynecol Oncol; 2021 Aug; 162(2):421-430. PubMed ID: 34088514
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Immune Cell Populations in Tumor Tissue and Peripheral Blood Samples from Head and Neck Squamous Cell Carcinoma Patients.
Caruntu A; Moraru L; Surcel M; Munteanu A; Tanase C; Constantin C; Zurac S; Caruntu C; Neagu M
Anal Cell Pathol (Amst); 2021; 2021():2328218. PubMed ID: 34692375
[TBL] [Abstract][Full Text] [Related]
15. Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response.
Cassim S; Pouyssegur J
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881671
[TBL] [Abstract][Full Text] [Related]
16. Cell competition in intratumoral and tumor microenvironment interactions.
Parker TM; Gupta K; Palma AM; Yekelchyk M; Fisher PB; Grossman SR; Won KJ; Madan E; Moreno E; Gogna R
EMBO J; 2021 Sep; 40(17):e107271. PubMed ID: 34368984
[TBL] [Abstract][Full Text] [Related]
17. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
[TBL] [Abstract][Full Text] [Related]
18. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
[No Abstract] [Full Text] [Related]
19. Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.
Gutkin DW; Shurin MR; El Azher MA; Shurin GV; Velikokhatnaya L; Prosser D; Shin N; Modugno F; Stemmer P; Elishaev E; Lokshin A
Cancer Biomark; 2019; 26(4):471-479. PubMed ID: 31658047
[TBL] [Abstract][Full Text] [Related]
20. In Silico implementation of evolutionary paradigm in therapy design: Towards anti-cancer therapy as Darwinian process.
Brutovsky B; Horvath D
J Theor Biol; 2020 Jan; 485():110038. PubMed ID: 31580834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
